<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366804</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00303</org_study_id>
    <nct_id>NCT04366804</nct_id>
  </id_info>
  <brief_title>International Validation of Two Non-motor Scales in PD (NFS and SPARK)</brief_title>
  <official_title>International Validation of Two Non-motor Scales in Parkinson's Disease: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in Parkinson's Disease (SPARK) Scale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to develop the international validation of two new rating scales,
      the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK)
      Scale, in order to improve the understanding of the extent and severity of non-motor symptoms
      in Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a prospective international multicentre study to validate two new rating
      scales in different languages: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in
      PARKinson's disease (SPARK) Scale.

      The project population consists a minimum of 300 PD patients with and without fluctuations in
      the participant countries: Spain, Germany, France, Switzerland, Romania and Greece.

      The NFS is specifically designed to detect neuropsychiatric fluctuations between off- and
      on-medication condition in PD. It is composed of 20 items, 10 items measuring the
      on-neuropsychological symptoms and 10 items for the off-neuropsychological manifestations.
      The validation of this scale, based on the most frequently experienced symptoms by the
      patients, would allow a crucial breakthrough in the improvement of management of PD patients.

      Shame and embarrassment are poorly recognized by physicians in PD. PD-related shame and
      embarrassment may emerge from motor and non-motor symptoms, from self-perception of
      inadequacy due to loss of autonomy and need for help, or from perceived deterioration of body
      image. The current available scales are not specific for PD. Based on reports of persons
      affected with PD and a literature review about shame and stigmatization in PD a 25-items
      self-questionnaire for shame and embarrassment in PD was created. The scale includes 6
      different subscales (1. Shame arising from PD symptoms; 2. Shame arising from the increasing
      physical dependence and need for help induced by PD; 3. Shame arising from the patient's
      assumption of breaking certain social rules; 4. Shame arising from the deteriorated body
      image; 5. Consequence of related shame and embarrassment on patients' health-related quality
      of life; 6. Stigmatization). The validation of this scale will give a tool for physicians and
      researchers to better understand the impact of PD on patient's quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NFS score</measure>
    <time_frame>2 weeks (2 assessments in a time span of 2 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SPARK score</measure>
    <time_frame>2 weeks (2 assessments in a time span of 2 weeks)</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Non-motor Symptoms</condition>
  <arm_group>
    <arm_group_label>Patients with neuropsychiatric fluctuations</arm_group_label>
    <description>PD patients with neuropsychiatric fluctuations (≥ 2 positive answers in QUICK test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without neuropsychiatric fluctuations</arm_group_label>
    <description>PD patients without neuropsychiatric fluctuations (≤ 1 positive answer in QUICK test)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The project population consists of PD patients with and without neuropsychiatric
        fluctuations attending routine visits to movement disorders clinics in the participant
        countries. Only patients capable of giving informed consent will be considered for
        participation in this project.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent;

          2. PD, according to the MDS criteria;

          3. Age of participants &gt; 30 and &lt; 75 years;

          4. Being fluent in the language in which the scales are applied.

        Exclusion Criteria:

        1. Presence of PD dementia (defined as MoCA score &lt; 24).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Krack, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Insel Gruppe AG University Hospital Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ines Debove, MD</last_name>
    <phone>+41 31 63 2 79 24</phone>
    <email>ines.debove@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier régional universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aristotle University of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>541 24</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Transilvania University</name>
      <address>
        <city>Brasov</city>
        <zip>500036</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruber International Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insel Gruppe AG University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Krack, MD, PhD</last_name>
      <email>paul.krack@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Ines Debove, MD</last_name>
      <email>ines.debove@insel.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>WC2R 2LS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Non-motor symptoms</keyword>
  <keyword>Scales for non-motor symptoms</keyword>
  <keyword>Validation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

